erythropoiesis

3-(3,4-Dimethoxyphenyl)propanoic acid (3,4-Dimethoxyhydrocinnamic acid) is an orally active short-chain fatty acid (SCFAs) that promotes γ-globin gene expression and erythropoiesis in vivo, making it useful in treating beta hemoglobinopathies and other anemias.

Mitapivat (PKR-IN-1), also known as PKM2 activator 1020 is a PKM2 activator (pyruvate kinase activator) for the treatment of pyruvate kinase deficiency.

Vadadustat is a novel, titratable, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor in development for the treatment of anemia.

JAK2-IN-13 is a potent and orally active JAK2 inhibitor with an IC50 of 54.7 nM. It downregulates the expression of p-STAT3 and p-STAT5 and exhibits good bioavailability. JAK2-IN-13 effectively suppresses recombinant human erythropoietin-induced extramedullary erythropoiesis as well as polycythemia vera. It is used in the study of myeloproliferative neoplasms.

Vamifeport (VIT-2763) is a novel orally active inhibitor that targets iron transport proteins and reduces markers of hemolysis in the SCD Townes model.VIT-2763 improves anemia and erythropoiesis, ameliorates vascular inflammation, and can be studied in β-thalassemia.

Roxadustat-D5 is intended for use as an internal standard for the quantification of roxadustat by GC- or LC-MS. Roxadustat (T2515) is an inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH; IC50s = 1.4, 1.26, and 1.32 µM for HIF-PH1, HIF-PH2, and HIF-PH3, respectively). It is selective for HIF-PH over other 2-oxoglutarate-dependent dioxygenases, including lysine-specific demethylase 5A (KDM5A), KDM5B, -5C, -5D, and -6B (IC50s = >100 µM for all). Roxadustat (T2515) (10-200 µM) stabilizes HIF-1α and HIF-2α in Hep3B hepatocellular carcinoma cells. It increases levels of secreted erythropoietin in Hep3B cells in a concentration-dependent manner and increases erythropoiesis in rats when administered at doses of 25 and 50 mg/kg. Roxadustat (T2515) reverses anemia in a rat model of chronic inflammation induced by peptidoglycan-polysaccharide, as well as a rat model of chronic kidney disease induced by 5/6 nephrectomy. It reduces tumor growth and increases survival in a murine Lewis lung carcin......

Epoetin zeta, a derivative of the endogenous protein erythropoietin, functions as an erythropoiesis-stimulating agent. It is utilized to investigate symptomatic anemia associated with renal disorders, referred to as symptomatic renal anemia [1].

Epoetin beta (rhEPO), a recombinant erythropoietin, is crucial for sustaining erythropoiesis and is utilized in anemia research [1].

LY2787106 is a humanized monoclonal antibody designed to neutralize bioactive human hepcidin-25. Hepcidin is the master hormonal regulator of systemic iron homeostasis, which limits iron release into the bloodstream by inducing the internalization and degradation of ferroportin, the only known cellular iron exporter. In states of chronic inflammation and cancer, abnormally elevated hepcidin causes iron sequestration. LY2787106 potently neutralizes circulating hepcidin, blocking its action on ferroportin and thereby mobilizing stored iron to increase serum iron levels and support erythropoiesis, specifically for managing cancer-associated anemia.

REGN7999 is a monoclonal antibody that inhibits TMPRSS6. By suppressing TMPRSS6 activity, REGN7999 prevents HJV cleavage, enhancing BMP6-HJV signaling and increasing serum hepcidin levels. This inhibition aids in alleviating iron overload and impaired erythropoiesis in β-thalassemia mouse models. REGN7999 is applicable for research in β-thalassemia.

Roxadustat-D5 (Standard) is a reference standard of Roxadustat-D5 intended for quantitative analysis, quality control, and related biochemical research applications. Roxadustat-d5 is intended for use as an internal standard for the quantification of roxadustat by GC- or LC-MS. Roxadustat is an inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH; IC50s = 1.4, 1.26, and 1.32 µM for HIF-PH1, HIF-PH2, and HIF-PH3, respectively). It is selective for HIF-PH over other 2-oxoglutarate-dependent dioxygenases, including lysine-specific demethylase 5A (KDM5A), KDM5B, -5C, -5D, and -6B (IC50s = >100 µM for all). Roxadustat (10-200 µM) stabilizes HIF-1α and HIF-2α in Hep3B hepatocellular carcinoma cells. It increases levels of secreted erythropoietin in Hep3B cells in a concentration-dependent manner and increases erythropoiesis in rats when administered at doses of 25 and 50 mg/kg. Roxadustat reverses anemia in a rat model of chronic inflammation induced by peptidoglycan-polysaccharide, as well as a rat model of chronic kidney disease induced by 5/6 nephrectomy. It reduces tumor growth and increases survival in a murine Lewis lung carcin......